Effects of Fumaric Acids on Cuprizone Induced Central Nervous System De- and Remyelination in the Mouse

Region-specific susceptibilities to cuprizone-induced lesions in the mouse forebrain: Implications for the pathophysiology of schizophrenia

(2009) Hong-Ju Yang et al.   BRAIN RESEARCH

Regional differences between grey and white matter in cuprizone induced demyelination

(2009) Viktoria Gudi et al.   BRAIN RESEARCH

Chronic toxic demyelination in the central nervous system leads to axonal damage despite remyelination

(2009) Maren Lindner et al.   NEUROSCIENCE LETTERS

The cuprizone model for demyelination

(2008) Ø. Torkildsen et al.   ACTA NEUROLOGICA SCANDINAVICA

Cortical Demyelination Is Prominent in the Murine Cuprizone Model and Is Strain-Dependent

(2008) Thomas Skripuletz et al.   AMERICAN JOURNAL OF PATHOLOGY

Multiple Sclerosis: An Immune or Neurodegenerative Disorder?

(2008) Bruce D. Trapp et al.   Annual Review of Neuroscience

Fumarates for the treatment of multiple sclerosis: potential mechanisms of action and clinical studies

(2008) Ralf A Linker et al.   Expert Review of Neurotherapeutics

The chemokine receptor CXCR2 is differentially regulated on glial cellsin vivo but is not required for successful remyelination after cuprizone-induced demyelination

(2008) Maren Lindner et al.   GLIA

Cuprizone treatment induces demyelination and astrocytosis in the mouse hippocampus

(2008) Akvile Norkute et al.   JOURNAL OF NEUROSCIENCE RESEARCH

Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

(2008) Ludwig Kappos et al.   LANCET